C

Concord Biotech Ltd
NSE:CONCORDBIO

Watchlist Manager
Concord Biotech Ltd
NSE:CONCORDBIO
Watchlist
Price: 2 071.3 INR -0.07% Market Closed
Market Cap: 216.7B INR
Have any thoughts about
Concord Biotech Ltd?
Write Note

Gross Margin
Concord Biotech Ltd

76%
Current
76%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
76%
=
Gross Profit
8.3B
/
Revenue
10.9B

Gross Margin Across Competitors

Country IN
Market Cap 216.7B INR
Gross Margin
76%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 749.7B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 372B USD
Gross Margin
69%
Country US
Market Cap 257.3B USD
Gross Margin
77%
Country CH
Market Cap 200.6B CHF
Gross Margin
73%
Country UK
Market Cap 162.5B GBP
Gross Margin
82%
Country CH
Market Cap 179.9B CHF
Gross Margin
75%
Country US
Market Cap 146B USD
Gross Margin
71%
No Stocks Found

Concord Biotech Ltd
Glance View

Market Cap
216.7B INR
Industry
Pharmaceuticals

Concord Biotech Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2023-08-18. Concord Biotech Limited is an India-based research and development driven biopharma company. The firm is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The firm manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. The company manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. The company also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The firm provides products in the critical care, immunology, nephrology, and transplant medicine segments.

CONCORDBIO Intrinsic Value
1 110.45 INR
Overvaluation 46%
Intrinsic Value
Price
C

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
76%
=
Gross Profit
8.3B
/
Revenue
10.9B
What is the Gross Margin of Concord Biotech Ltd?

Based on Concord Biotech Ltd's most recent financial statements, the company has Gross Margin of 76%.